biotin has been researched along with sanorg 34006 in 9 studies
| Studies (biotin) | Trials (biotin) | Recent Studies (post-2010) (biotin) | Studies (sanorg 34006) | Trials (sanorg 34006) | Recent Studies (post-2010) (sanorg 34006) |
|---|---|---|---|---|---|
| 14,847 | 95 | 3,882 | 89 | 14 | 25 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eikelboom, J; O'Donnell, M; Sobieraj-Teague, M | 1 |
| de Kort, M; Dubreucq, G; Meuleman, D; Motte, V; Nancy-Portebois, V; Petitou, M; van Boeckel, CA; Vogel, GM; Wisse, JA | 1 |
| Harenberg, J | 1 |
| Alame, G; Cazenave, JP; Freund, M; Gachet, C; Gaertner, S; Hechler, B; Leguay, C; Petitou, M | 1 |
| Boëlle, E; Cheng, S; Cortez, P; Donat, F; Fau, JB; Paty, I; Sanderink, GJ; Trellu, M | 1 |
| Li, D; Li, X; Pavithra, S; Song, Y | 1 |
| Driguez, PA; Potier, P; Trouilleux, P | 1 |
| Brandao, GM; Junqueira, DR; Rollo, HA; Sobreira, ML | 1 |
6 review(s) available for biotin and sanorg 34006
| Article | Year |
|---|---|
New anticoagulants for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; Biotin; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K | 2009 |
From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
Topics: Animals; Anticoagulants; Antithrombin III; Avidin; Binding Sites; Biotin; Drug Design; Factor Xa Inhibitors; Fondaparinux; Heparin; Heparin Antagonists; Humans; Molecular Structure; Oligosaccharides; Polysaccharides; Rabbits; Structure-Activity Relationship; Thrombosis | 2009 |
Development of idraparinux and idrabiotaparinux for anticoagulant therapy.
Topics: Animals; Anticoagulants; Antithrombin III; Atrial Fibrillation; Avidin; Biotin; Carbohydrate Conformation; Carbohydrate Sequence; Drug Design; Drug Evaluation, Preclinical; Fondaparinux; Hemorrhage; Heparin Antagonists; Humans; Molecular Sequence Data; Molecular Structure; Oligosaccharides; Polysaccharides; Randomized Controlled Trials as Topic; Structure-Activity Relationship; Thrombosis; Treatment Outcome | 2009 |
Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials.
Topics: Biotin; Humans; Oligosaccharides; Randomized Controlled Trials as Topic; Venous Thromboembolism | 2013 |
Synthetic oligosaccharides as active pharmaceutical ingredients: lessons learned from the full synthesis of one heparin derivative on a large scale.
Topics: Biotin; Fondaparinux; Heparin; Molecular Structure; Oligosaccharides; Polysaccharides; Structure-Activity Relationship | 2014 |
Pentasaccharides for the treatment of deep vein thrombosis.
Topics: Anticoagulants; Biotin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Oligosaccharides; Polysaccharides; Randomized Controlled Trials as Topic; Recurrence; Time Factors; Venous Thrombosis | 2017 |
2 trial(s) available for biotin and sanorg 34006
| Article | Year |
|---|---|
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.
Topics: Adult; Aged; Anticoagulants; Biotin; Blood Coagulation; Double-Blind Method; Drug Administration Schedule; Europe; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Oligosaccharides; Recurrence; Risk Assessment; Time Factors; Treatment Outcome; United States; Venous Thrombosis | 2011 |
Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.
Topics: Adolescent; Adult; Anticoagulants; Area Under Curve; Biotin; Factor Xa; Factor Xa Inhibitors; Humans; Male; Middle Aged; Oligosaccharides; Therapeutic Equivalency; Venous Thrombosis; Young Adult | 2013 |
1 other study(ies) available for biotin and sanorg 34006
| Article | Year |
|---|---|
The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds.
Topics: Animals; Biotin; Disease Models, Animal; Drug Combinations; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligosaccharides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Thromboembolism; Tirofiban; Tyrosine | 2011 |